We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.
- Authors
DeNardo, G L; DeNardo, S J; Goldstein, D S; Kroger, L A; Lamborn, K R; Levy, N B; McGahan, J P; Salako, Q; Shen, S; Lewis, J P
- Abstract
Lym-1, a monoclonal antibody that preferentially targets malignant lymphocytes, has induced remissions in patients with non-Hodgkin's lymphoma (NHL) when labeled with iodine 131 ((131)I). Based on the strategy of fractionating the total dose, this study was designed to define the maximum-tolerated dose (MTD) and efficacy of the first two, of a maximum of four, doses of (131)I-Lym-1 given 4 weeks apart. Additionally, toxicity and radiation dosimetry were assessed.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Vol 16, Issue 10, p3246
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.1998.16.10.3246